


Date/ time: Wednesday, April 12, 2023 at 1pm via Webex

Join meeting: <https://umm.webex.com/umm/j.php?MTID=m203d143658eb40d6c06120d5687e0ecd>

Topic: Modulation of amino acid metabolism for the treatment of AML

Acute myeloid leukemia (AML) cells are sensitive to depletion of extracellular glutamine or manipulation of glutamine metabolism. We recently reported the synergistic anti-leukemic activity of the combination of the Bcl-2 inhibitor Venetoclax (Ven) and the Erwinia asparaginase pegcrisantaspase (PegC) in complex karyotype AML. Our promising pre-clinical data prompted us to design a Phase 1 clinical trial of Ven-PegC for treatment of adult subjects with R/R AML, which is currently ongoing.



Dominique Bollino, PhD

Research Associate
Department of Medicine
University of Maryland School of Medicine



Ashkan Emadi, MD, PhD

Professor, Medicine and Pharmacology
Associate Director for Clinical Research UMGCCC
Director, Translational Genomic Laboratory UMSOM